These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 22253234)
1. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Lacaná E; Yao LP; Pariser AR; Rosenberg AS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234 [TBL] [Abstract][Full Text] [Related]
2. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Kishnani PS; Beckemeyer AA; Mendelsohn NJ Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049 [TBL] [Abstract][Full Text] [Related]
3. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Case LE; Beckemeyer AA; Kishnani PS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989 [TBL] [Abstract][Full Text] [Related]
4. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Kishnani PS; Beckemeyer AA Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093 [TBL] [Abstract][Full Text] [Related]
6. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease. Wang Z; Okamoto P; Keutzer J Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983 [TBL] [Abstract][Full Text] [Related]
8. New insights into therapeutic options for Pompe disease. Richard E; Douillard-Guilloux G; Caillaud C IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928 [TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy for infantile-onset Pompe disease. Chen M; Zhang L; Quan S Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436 [TBL] [Abstract][Full Text] [Related]
10. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease. Douillard-Guilloux G; Richard E; Batista L; Caillaud C J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466 [TBL] [Abstract][Full Text] [Related]
11. Pompe disease: early diagnosis and early treatment make a difference. Chien YH; Hwu WL; Lee NC Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029 [TBL] [Abstract][Full Text] [Related]
12. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258 [TBL] [Abstract][Full Text] [Related]
13. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098 [TBL] [Abstract][Full Text] [Related]
14. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258 [TBL] [Abstract][Full Text] [Related]
15. 24-months results in two adults with Pompe disease on enzyme replacement therapy. Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922 [TBL] [Abstract][Full Text] [Related]
16. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Bernstein DL; Bialer MG; Mehta L; Desnick RJ Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881 [TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Klinge L; Straub V; Neudorf U; Voit T Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317 [TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673 [TBL] [Abstract][Full Text] [Related]
19. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]